Table 3 Grade-3 and higher adverse event results according to the treatment group.

From: Comparison of anthracycline-containing and anthracycline-free regimens in neoadjuvant HER-2 positive breast cancer treatment

 

Arm A

Arm B

p value

n (%)

n (%)

Anemia

3 (6.0)

6 (6.5)

0.99

Thrombocytopenia

3 (6.0)

0 (0.0)

0.04a

Lokopenia

1 (2.0)

4 (4.3)

0.65

Neutropenia

3 (6.0)

9 (9.8)

0.54

Nausea

6 (12.0)

10 (10.9)

0.83

Vomiting

2 (4.0)

5 (5.4)

0.99

Mucositis

1 (2.0)

0 (0.0)

0.35

Fatigue

9 (18.0)

10 (10.9)

0.23

Diarrhea

3 (6.0)

8 (8.7)

0.74

Rash

1 (2.0)

1 (1.1)

0.99

Hepatotoxicity

1 (2.0)

0 (0.0)

0.35

Neuropathy

1 (2.0)

1 (1.1)

0.99

  1. aStatistically significant.